Document Detail


Modification of serum lipids and cardiovascular risk by estrogenic active compounds.
MedLine Citation:
PMID:  10862265     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardiovascular disease is an important cause of death among women. After the menopause there is a steep elevation of low-density lipoprotein (LDL) cholesterol and lipoprotein(a) concomitantly with other risk factors, followed by a striking increase in arteriosclerotic vascular disease, compatible with a lack of estrogens as a causative factor. The benefit of hormone replacement therapy has been documented in several large studies, although rigorous randomized trials are still under way. However, cardiovascular events have been reduced by approximately 50%. In order to optimize beneficial effects and minimize side-effects, the characteristics of selective estrogenic active compounds are a major target of research. The anti-estrogens are the prototype of partial and selective estrogen functions. The components of conjugated estrogens are under investigation for their specific effects. For example, both 17 alpha-dihydroequilin sulfate and 17 alpha-dihydroequilenin sulfate seem to exert antioxidant activity without significant proliferative effects on uterine or breast tissues. This suggests a selective estrogenic activity dependent on the predominant type of estrogen receptor in the particular tissue. Equilin sulfate exerts a significantly stronger antioxidant activity than 17 beta-estradiol in vitro, and delta 8-estrone sulfate increases the lag time for low-density lipoprotein oxidation in vivo. These actions on lipoproteins may add to the quantitative changes of lipoproteins, while other effects are independent of lipoproteins. The 17 alpha-dihydroequilin sulfate and equilin sulfate improved the action of insulin in vivo. Data from rhesus monkeys treated with 17 alpha-dihydroequilenin sulfate indicate that additional mechanisms are probably responsible for the observed cardiovascular protection. Further studies need to be conducted in order to identify selective estrogen receptor modulators and assess their potential, especially in lowering cardiovascular risk.
Authors:
E Windler
Related Documents :
22442505 - Reproductive performance after hysteroscopic metroplasty in women with primary infertil...
10471985 - Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women.
16915215 - Clinical opinion: the biologic and pharmacologic principles of estrogen therapy for sym...
16202725 - Body mass, estrogen levels, and hot flashes in midlife women.
10494225 - Osteoporosis in older men: discovering when and how to treat it.
22950595 - The relationship between microalbuminuria, left ventricular hypertrophy, retinopathy, a...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology     Volume:  13 Suppl 6     ISSN:  0951-3590     ISO Abbreviation:  Gynecol. Endocrinol.     Publication Date:  1999 Dec 
Date Detail:
Created Date:  2000-07-13     Completed Date:  2000-07-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8807913     Medline TA:  Gynecol Endocrinol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  21-8     Citation Subset:  IM    
Affiliation:
University Hospital Eppendorf, Hamburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Cardiovascular Diseases / epidemiology,  prevention & control*
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Estrogens, Conjugated (USP) / therapeutic use*
Female
Hormone Replacement Therapy*
Humans
Hyperlipidemias / epidemiology,  pathology,  prevention & control*
Medroxyprogesterone / therapeutic use
Menopause
Middle Aged
Risk Factors
Selective Estrogen Receptor Modulators / therapeutic use*
Chemical
Reg. No./Substance:
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Estrogens, Conjugated (USP); 0/Selective Estrogen Receptor Modulators; 520-85-4/Medroxyprogesterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Conjugated estrogens and breast cancer risk.
Next Document:  Role of progestins in the premenopausal climacteric.